Clinical Pharmacology
Managed care approach to substance abuse treatment
MAY 20, 2013An examination of people’s behaviors as they relate to drug use in the 20th century has shown that people will expend a large amount of energy to acquire any agent that has the ability to alter their minds, bodies, or behaviors in order to achieve a euphoric effect.
MAY 20, 2013An examination of people’s behaviors as they relate to drug use in the 20th century has shown that people will expend a large amount of energy to acquire any agent that has the ability to alter their minds, bodies, or behaviors in order to achieve a euphoric effect.
Seizure drug may turn skin blue
APRIL 30, 2013
APRIL 30, 2013
By: STAFF REPORTS
A medication used to treat seizures, ezogabine (Potiga, Valeant), can cause blue skin discoloration, the Food and Drug Administration (FDA) warns, and it is unknown whether the pigmentation changes are reversible.Dabigatran as effective as warfarin to prevent VTE recurrence
APRIL 15, 2013Data from the RE-MEDY trial suggest that Pradaxa is as effective as warfarin for long-term, extended antithrombotic therapy in patients who have already received at least three months of anticoagulation for VTE
APRIL 15, 2013Data from the RE-MEDY trial suggest that Pradaxa is as effective as warfarin for long-term, extended antithrombotic therapy in patients who have already received at least three months of anticoagulation for VTE
FDA approves 3 new therapies for type 2 diabetes
APRIL 15, 2013Alogliptin approved as monotherapy and in two combinations
APRIL 15, 2013Alogliptin approved as monotherapy and in two combinations
FDA approval marks new drug class for type 2 diabetes
APRIL 10, 2013
APRIL 10, 2013
By: JULIA BROWN
Canaglifozin (Invokana, Janssen Pharmaceuticals) tablets, recently approved by the U.S. Food and Drug Administration for the improvement of glycemic control in adults with type 2 diabetes, is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 inhibitors.Guideline recommendations issued for molecular testing, targeted therapies in lung cancer
APRIL 08, 2013
APRIL 08, 2013
By: FORMULARY STAFF
The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) recently issued evidence-based guidelines on molecular testing in lung cancer, and support the recommendation that physicians conduct testing in advanced non-small cell lung cancer patients at the time of diagnosis or at the time of recurrence or progression.First drug approved specifically for multi-drug resistant tuberculosis
MARCH 15, 2013FDA approved bed aquiline tablets late last year for the treatment of pulmonary multi-drug-resistant tuberculosis.
MARCH 15, 2013FDA approved bed aquiline tablets late last year for the treatment of pulmonary multi-drug-resistant tuberculosis.
Apixaban added to anticoagulant arsenal
MARCH 15, 2013FDA recently approved apixaban for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
MARCH 15, 2013FDA recently approved apixaban for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
New strategies needed to reduce mortality associated with cardiometabolic risk factors in young people
FEBRUARY 28, 2013
FEBRUARY 28, 2013
By: TRACEY WALKER
Among US adolescents and young adults, HbA1c levels, central obesity, and smoking were associated with an increased risk of dying before 55 years of age.Researchers seek next class of anti-allergics
FEBRUARY 28, 2013
FEBRUARY 28, 2013
By: PAULO J. GOMES
Allergy season is almost upon us and anti-histamine agents remain the top choice. However, researchers are looking for new medications to help patients with different needs.